Synthesis and studies molecular docking of some new thioxobenzo[g]pteridine derivatives and 1,4-dihydroquinoxaline derivatives with glycosidic moiety

References

• Xiang J, Zheng L, Chen F, et al. A cascade reaction consisting of pictet- spengler-type cyclization and smiles rearrangement: application to the synthesis of novel pyrrole-fused dihydropteridines. Org Lett. 2007;9:765–767. doi: 10.1021/ol0629364
   Google Scholar
• Asif M. The pharmacological importance of some diazine containing drug molecules. Sop Trans. Org. Chem. 2014;1:1–10. doi: 10.15764/STAC.2014.01001
   Google Scholar
• Rinderspacher A. Six-Membered ring systems: diazines and benzo derivatives, progress in heterocyclic chemistry. Elsevier. 2013;25:357–390.
   Google Scholar
• Gourley DG, Schüttelkopf AW, Leonard GA, et al. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites. Nat Struct Mol Biol. 2001;8:521–525. doi: 10.1038/88584
   Google Scholar
• Schüttelkopf AW, Hardy LW, Beverley SM, et al. Structures of leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. J Mol Biol. 2005;352:105–116. doi: 10.1016/j.jmb.2005.06.076
   Google Scholar
• Vickers TJ, Orsomando G, de la Garza RD, et al. Biochemical and genetic analysis of methylenetetrahydrofolate reductase in leishmania metabolism and virulence. J Biol Chem. 2006;281:38150–38158. doi: 10.1074/jbc.M608387200
   Google Scholar
• Voet D, Voet J, Pratt C. Electron transport, and oxidative phosphorylation, biochemistry. 3rd ed. Hoboken (NJ): John Wiley & Sons; 2004; 797–842 DOI.
   Google Scholar
• Cushman M, Patel HH, Scheuring J, et al. Fluorine-19 NMR studies on the mechanism of riboflavin synthase. synthesis of 6-(trifluoromethyl)-7-oxo-8-(D-ribityl) lumazine and 6-(trifluoromethyl)-7-methyl-8-(D-ribityl) lumazine. J Org Chem. 1992;57:5630–5643. doi: 10.1021/jo00047a015
   Google Scholar
• Climent T, González-Luque R, Merchán M, et al. Theoretical insight into the spectroscopy and photochemistry of isoalloxazine, the flavin core ring. J Phys Chem A. 2006;110:13584–13590. doi: 10.1021/jp065772h
   Google Scholar
• Goodwill KE, Sabatier C, Stevens RC. The crystal structure of tyrosine hydroxylase with bound cofactor analog and iron at 2.3 Å resolution: self-hydroxylation of Phe300 and the pterin-binding site. Biochem. 1998;37:13437–13445. doi: 10.1021/bi981462g
   Google Scholar
• Negishi E-i, Hu Q, Huang Z, et al. Palladium-catalyzed alkenylation by the negishi coupling. Aldrichim Acta. 2005;38:71–87.
   Google Scholar
• Venters D. Folate synthesis in Ae. aegypti and drosophila melanogaster larvae. Trans R Soc Trop Med Hyg. 1971;65:687–688. doi: 10.1016/0035-9203(71)90063-0
   Google Scholar
• Xu H, Fan L-l. Synthesis and antifungal activities of novel 5, 6-dihydro-indolo [1, 2-a] quinoxaline derivatives. Eur J Med Chem. 2011;46:1919–1925. doi: 10.1016/j.ejmech.2011.02.035
   Google Scholar
• Corbett TH, LoRusso P, Demchick L, et al. Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy) phenoxy] propionate. Invest New Drugs. 1998;16:129–139. doi: 10.1023/A:1006174622061
   Google Scholar
• Budakoti A, Bhat AR, Azam A. Synthesis of new 2-(5-substituted-3-phenyl-2-pyrazolinyl)-1, 3-thiazolino [5, 4-b] quinoxaline derivatives and evaluation of their antiamoebic activity. Eur J Med Chem. 2009;44:1317–1325. doi: 10.1016/j.ejmech.2008.02.002
   Google Scholar
• Tandon VK, Yadav DB, Maurya HK, et al. Design, synthesis, and biological evaluation of 1, 2, 3-trisubstituted-1, 4-dihydro benzo [g] quinoxaline-5, 10-diones and related compounds as antifungal and antibacterial agents. Bioorg Med Chem. 2006;14:6120–6126. doi: 10.1016/j.bmc.2006.04.029
   Google Scholar
• Carta A, Paglietti G, Nikookar MER, et al. Novel substituted quinoxaline 1, 4-dioxides with in vitro antimycobacterial and anticandida activity. Eur J Med Chem. 2002;37:355–366. doi: 10.1016/S0223-5234(02)01346-6
   Google Scholar
• Hui X, Desrivot J, Bories C, et al. Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines. Bioorg Med Chem Lett. 2006;16:815–820. doi: 10.1016/j.bmcl.2005.11.025
   Google Scholar
• Noolvi MN, Patel HM, Bhardwaj V, et al. Synthesis and in the vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for an anticancer agent. Eur J Med Chem. 2011;46:2327–2346. doi: 10.1016/j.ejmech.2011.03.015
   Google Scholar
• Abu-Hashem A, Gouda M, Badria F. Synthesis of some new pyrimido [2′, 1′: 2, 3] thiazolo [4, 5-b] quinoxaline derivatives as anti-inflammatory and analgesic agents. Eur J Med Chem. 2010;45:1976–1981. doi: 10.1016/j.ejmech.2010.01.042
   Google Scholar
• Wagle S, Adhikari AV, Kumari NS. Synthesis of some new 2-(3-methyl-7-substituted-2-oxoquinoxalinyl)-5-(aryl)-1, 3, 4-oxadiazoles as potential non-steroidal anti-inflammatory and analgesic agents. Ind J Chem. 2008;47:439–448.
   Google Scholar
• Singh DP, Hashim SR, Singhal RG. Anti-inflammatory activity of some new thioether derivatives of quinoxaline. Int. J. Drug Dev. Res. 2010;2:810–815.
   Google Scholar
• Bakr RB, Azouz AA, Abdellatif KR. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo [3, 4-d] pyrimidine derivatives. J Enzyme Inhib Med Chem. 2016;31:6–12. doi: 10.1080/14756366.2016.1186018
   Google Scholar
• Abdelgawad MA, Bakr RB, El-Gendy AO, et al. Discovery of a COX-2 selective inhibitor hit with anti-inflammatory activity and gastric ulcer protective effect. Future Med Chem. 2017;9:1899–1912. doi: 10.4155/fmc-2017-0115
   Google Scholar
• Abdelgawad MA, Bakr RB, Alkhoja OA, et al. Design, synthesis and antitumor activity of novel pyrazolo [3, 4-d] pyrimidine derivatives as EGFR-TK inhibitors. Bioorg Chem.. 2016;66:88–96. doi: 10.1016/j.bioorg.2016.03.011
   Google Scholar
• Bakr RB, Mehany ABM, Abdellatif KRA. Synthesis, EGFR inhibition and anti-cancer activity of New 3, 6-dimethyl-1-phenyl-4-(substituted-methoxy) pyrazolo [3, 4-d] pyrimidine derivatives. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2017;17:1389–1400.
   Google Scholar
• Abdellatif KRA, Abdelall EKA, Bakr RB. Nitric oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents. Curr Top Med Chem. 2017;17:941–955. doi: 10.2174/1568026616666160927153435
   Google Scholar
• Khalafallah A, Abd El-Aal R, El-Kanzi N. Synthesis of several polyfunctionally substituted fused pyrimidines incorporating quinone compounds. J Chin Chem Soc. 2004;51:769–774. doi: 10.1002/jccs.200400116
   Google Scholar
• Soleiman H, Elkanzi N. Heterocyclic synthesis containing New spiro, isolated (β-Lactam and Thiazolidinone) 3-cyano-2, 4-diamino thiophene derivatives. Phosphorus, Sulfur, and Silicon. 2008;183:1679–1690. doi: 10.1080/10426500701724548
   Google Scholar
• El Azab IH, Elkanzi NA, Gobouri AA. Design and synthesis of some New quinoxaline-based heterocycles. J Heterocycl Chem. 2018;55:65–76. doi: 10.1002/jhet.2978
   Google Scholar
• Harizi H, Corcuff J-B, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med. 2008;14:461–469. doi: 10.1016/j.molmed.2008.08.005
   Google Scholar
• Tzeng S-F, Hsiao H-Y, Mak O-T. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Current Drug Targets-Inflammation & Allergy. 2005;4:335–340. doi: 10.2174/1568010054022051
   Google Scholar
• Leone S, Ottani A, Bertolini A. Dual acting anti-inflammatory drugs. Curr Top Med Chem. 2007;7:265–275. doi: 10.2174/156802607779941341
   Google Scholar
• Dogné J-M, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem.. 2005;48:2251–2257. doi: 10.1021/jm0402059
   Google Scholar
• Sigthorsson G, Crane R, Simon T, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut. 2000;47:527–532. doi: 10.1136/gut.47.4.527
   Google Scholar
• Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American heart association. Circulation. 2007;115:1634–1642. doi: 10.1161/CIRCULATIONAHA.106.181424
   Google Scholar
• Dogne J-M, Hanson J, Supuran C, et al. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des. 2006;12:971–975. doi: 10.2174/138161206776055949
   Google Scholar
• Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550–557. doi: 10.1021/jm030912m
   Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098. doi: 10.1371/journal.pmed.1001098
   Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. doi: 10.1136/bmj.c7086
   Google Scholar
• Habeeb AG, Praveen Rao P, Knaus EE. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. J Med Chem. 2001;44:3039–3042. doi: 10.1021/jm010153c
   Google Scholar